$5.390
-0.127 (-2.36%)At close
SCYX News
SCYX Events
SCYNEXIS Reports Q2 Revenue of $235,000, Exceeding Expectations
Reports Q2 revenue $235,000, consensus $80,330. "The initiation of our Phase 1 study marks an important milestone in the advancement of SCY-770 and our commitment to developing a potentially transformative treatment for patients living with ADPKD, a disease that affects about 140,000 patients in the United States alone," said David Angulo, President and Chief Executive Officer of SCYNEXIS. "SCY-770 is a highly selective orally available direct AMPK activator designed to address multiple underlying drivers of cyst growth and disease progression. Supported by compelling preclinical data and a well-characterized safety profile, we believe that SCY-770 has the potential to offer a differentiated therapeutic approach for this underserved patient population. We are encouraged by the progress of the program and remain on track to initiate our Phase 2 proof-of-concept trial later this year."
Scynexis Initiates Phase 1 Study of SCY-770
Scynexis announced initiation of a Phase 1 study of SCY-770, an AMP-activated protein kinase activator. The study will characterize the food-effect and define the pharmacokinetics of two dosing regimens for SCY-770 to support dose selection for the Phase 2 study in patients with Autosomal Dominant Polycystic Kidney Disease, on track for Q4.
Scynexis Trading Halted, News Pending
Scynexis trading halted, news pending
Company Cash and Investments Total $72.4 Million
Cash, cash equivalents and investments totaled $72.4M on March 31, compared to $56.3M on December 31, 2025. The balance at March 31 includes approximately $24M of the gross proceeds of $40M from the private placement that closed on April 1 with certain new and existing institutional and accredited investors. The March 31 balance plus the approximately $16M in gross proceeds received on April 1 extends the company's cash runway to mid-2029.
Scynexis Files to Sell 87M Shares of Common Stock
Scynexis files to sell 87M shares of common stock for holders
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.